Overview

A Trial of Antroquinonol in Patients With Atopic Dermatitis

Status:
Completed
Trial end date:
2019-07-09
Target enrollment:
Participant gender:
Summary
This is a multi-centers, phase IIa, double blind, randomized, placebo-controlled trial of Antroquinonol in patients with atopic dermatitis.Duration of treatment is 12 week in total. Study visits will occur every 4 weeks. AEs/SAEs, changes to concomitant medications will be noted, vital signs will be taken, and efficacy evaluations will be performed as well. The last estimation of variable scores will occur for all subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Golden Biotechnology Corporation
Treatments:
Ubiquinone